Vericel to Present at Truist Securities MedTech Conference on June 18, 2024

In CAMBRIDGE, Massachusetts, Vericel Corporation, a prominent entity in the field of advanced therapies for sports medicine and severe burn care, has recently made an important announcement. The company's President and CEO, Nick Colangelo, along with CFO Joe Mara, are slated to participate in a fireside chat at the Truist Securities MedTech Conference. This event is scheduled for 2:30 p.m. ET on Tuesday, June 18, 2024. For those interested, a webcast of their presentation will be accessible via the Investor Relations section on the Vericel Corporation website.

Vericel Corporation stands at the forefront of providing cutting-edge therapies specifically designed for sports medicine and the treatment of severe burns. The company's innovative approach integrates biological advancements with medical technologies, creating a unique and specialized portfolio aimed at injury repair and life restoration. Among the notable products marketed by Vericel in the United States are MACI®, Epicel®, and NexoBrid®.

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a cellular scaffold product used to repair symptomatic, full-thickness cartilage defects in the knee, with or without bone involvement, in adult patients. This product is tailored to address multiple or single cartilage defects, offering a personalized treatment approach.

Epicel® (cultured epidermal autografts) serves as a permanent skin replacement therapy for patients who have suffered deep dermal or full-thickness burns covering 30% or more of their total body surface area. This advanced treatment is crucial for those with extensive burn injuries, providing a vital solution for skin regeneration and healing.

Vericel also possesses the exclusive North American license for NexoBrid® (anacaulase-bcdb), a biologically derived orphan product that contains proteolytic enzymes used for eschar removal in adults with deep partial-thickness and/or full-thickness burns. NexoBrid® plays a significant role in burn management by facilitating the removal of dead tissue, thereby promoting faster and more effective healing.

These products, Epicel and MACI, are registered trademarks of Vericel Corporation, while NexoBrid is a registered trademark of MediWound Ltd., licensed exclusively to Vericel Corporation in North America.

Vericel Corporation's dedication to innovation and patient care is evident through its development and marketing of these advanced therapeutic solutions. The upcoming participation of Nick Colangelo and Joe Mara in the Truist Securities MedTech Conference highlights the company's ongoing commitment to advancing medical technology and providing state-of-the-art treatments for critical conditions in sports medicine and burn care.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!